ArticleClinical epidemiology2023
Disease Burden of Total and Early-Onset Colorectal Cancer in China from 1990 to 2019 and Predictions of Cancer Incidence and Mortality.
Article in Clinical epidemiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Exploring the impact and mechanisms of behavioral activation on sleep disorders in colorectal cancer: a randomized controlled trial.Journal of cancer research and clinical oncology · 2024Trial
- Cost-Effectiveness of Initiating Colorectal Cancer Screening at Age 40 Among Average-Risk Individuals in China.International journal of cancer · 2026Article
- A case-control study of dietary patterns and lifestyle factors affecting colorectal cancer in Hunan province, South China.Medicine · 2026Article
- Review
- Review
- Oxaliplatin upregulates Cyr61 expression by inhibiting the Hippo-YAP pathway which contributes to drug resistance of colorectal cancer cells.Discover oncology · 2026Article
- The Evolving Landscape of Colorectal Cancer: Aging Burden and Metabolic Risk Factors in China (1990-2021).Journal of gastrointestinal cancer · 2026Article
- Chenodeoxycholic acid suppresses colorectal cancer by activating Farnesoid X receptor.American journal of cancer research · 2026Article
- Secular trend of colorectal cancer related with low physical activity from 1990 to 2021 in China.BMC cancer · 2025Article
- Article
- Clinical profiles and health-related quality of life changes after treatment in advanced colorectal cancer patients: a nationwide study in China.BMC cancer · 2025Article
- NF-κB and apoptosis: colorectal cancer progression and novel strategies for treatment.European journal of medical research · 2025Review
- Discovery and Validation of Novel Biomarkers for Colorectal Neoplasia Detection via Plasma Metabolomics.MedComm · 2025Article
- Prognosis and clinicopathological features of patients with early-onset and late-onset colorectal cancer with second primary malignancies.Journal of gastroenterology and hepatology · 2025Article
- The global, regional, and national burden of colorectal cancer and its attributable risk factors in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021.Frontiers in oncology · 2025Article
- Case Report: Masquerading doughnut: a case of misdiagnosed ileocecal tumor-induced intussusception.Frontiers in oncology · 2025Article
- Global burden and cross-country health inequalities of early-onset colorectal cancer and its risk factors from 1990 to 2021 and its projection until 2036.BMC public health · 2024Article
- The role of chromatin modulator DPY30 in glucose metabolism of colorectal cancer cells.Translational cancer research · 2024Article
- Diagnostic performances of methylated septin9 gene, CEA, CA19-9 and platelet-to-lymphocyte ratio in colorectal cancer.BMC cancer · 2024Article
- Nomogram model for predicting cancer-specific mortality in patients with early-onset colorectal cancer: a competing risk analysis insight from the SEER database and an external validation cohort.Translational cancer research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding the temporal trends in the epidemiology of colorectal cancer (CRC) and early-onset CRC (EOCRC) in China is essential for policymakers to develop appropriate strategies to reduce the CRC burden. Methods: The prevalence, incidence, mortality, years of life lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life years (DALYs) of CRC were obtained from the Global Burden of Disease (GBD) Study 2019. The incidence and mortality of CRC over the next 25 years were predicted. Results: From 1990 to 2019, the prevalence, incidence, and mortality of total CRC and EOCRC significantly increased in males, with milder trends in females. In 2019, the number of people living with CRC (or EOCRC) in China was approximately 3.4 (0.59) million, which was over seven (five) times higher than that in 1990. The DALYs, YLDs, and YLLs moderately increased from 1990 to 2019 in both sexes. The age-standardized mortality rate (ASMR) for females has shown a stable trend in total CRC, and a downward trend in EOCRC since 2000. While the ASMR for males showed increasing trends in total CRC and EOCRC. In 2019, the highest incidence, prevalence, YLDs, YLLs, and DALYs were all observed in the 65 to 69 age group, while the highest mortality was in the 70 to 74. By 2044, the incidence and deaths of CRC are expected to reach 1310 thousand and 484 thousand, respectively. For EOCRC, the incidence will peak at about 101 thousand around 2034, and the mortality will continuously decrease to a nadir at about 18 thousand around 2044. Conclusion: Although the age-standardized incidence and mortality of total CRC and EOCRC in China will reach a plateau, the number of incident cases and deaths of CRC have been increasing in the last three decades and will continue to increase in the next 25 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.